Physician profile
Larry Balle
NPI 1508283995
$20,945.76
in general payments reported to CMS, 2019-2025
15 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,867 · 2020: $90.94 · 2024: $247 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Consulting Fee: $3,000 · Travel and Lodging: $2,351 · Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $2,351.10 |
| Food and Beverage | $2,136.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $14,731.74 | 2019-2025 | Xcell, Durolane |
| Avanos Medical | $3,640.80 | 2019-2025 | Coolief Cooled Radiofrequency |
| Medinc of Texas | $1,152.31 | 2025 | |
| Horizon Therapeutics Plc | $315.84 | 2019-2020 | |
| Arthrex, INC. | $268.20 | 2025 | |
| Zimmer Biomet Holdings, INC. | $264.14 | 2024-2025 | Gel-One Cross-Linked Hyaluronate, Gps III Platelet Concentration System |
| Trice Medical, INC. | $258.33 | 2025 | |
| Amgen INC. | $69.10 | 2024-2025 | Krystexxa |
| Stryker Corporation | $67.39 | 2020-2024 | Regenkit-Tht |
| Pacira Therapeutics, INC. | $58.05 | 2019 | |
| Depuy Synthes Sales INC. | $39.70 | 2019-2025 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $29.02 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $22.98 | 2025 | Iovera, Zilretta |
| Shield Therapeutics INC | $16.49 | 2025 | |
| Ferring Pharmaceuticals INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Balle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.